PSA testing: what is the use?

被引：16

作者：

Crawford, ED ^{[1
]}

机构：

[1] Univ Colorado, Denver, CO 80262 USA

来源：

LANCET | 2005年 / 365卷 / 9469期

关键词：

D O I：

10.1016/S0140-6736(05)66398-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1447 / 1449

页数：3

共 11 条

[1] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial [J].

Andriole, GL ;

Levin, DL ;

Crawford, ED ;

Gelmann, ER ;

Pinsky, PF ;

Chia, D ;

Kramer, BS ;

Reding, D ;

Church, TR ;

Grubb, RL ;

Izmirlian, G ;

Ragard, LR ;

Clapp, JD ;

Prorok, PC ;

Gohagan, JK .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) :433-438

[2] Trends in prostate cancer mortality among black men and white men in the United States [J].

Chu, KC ;

Tarone, RE ;

Freeman, HP .

CANCER, 2003, 97 (06) :1507-1516

[3]

Crawford ED, 1999, PROSTATE, V38, P296

[4] Epidemiology of prostate cancer [J].

Crawford, ED .

UROLOGY, 2003, 62 (6A) :3-12

[5] The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].

McConnell, JD ;

Roehrborn, CG ;

Bautista, OM ;

Andriole, GL ;

Dixon, CM ;

Kusek, JW ;

Lepor, H ;

McVary, KT ;

Nyberg, LM ;

Clarke, HS ;

Crawford, ED ;

Diokno, A ;

Foley, JP ;

Foster, HE ;

Jacobs, SC ;

Kaplan, SA ;

Kreder, KJ ;

Lieber, MM ;

Lucia, MS ;

Miller, GJ ;

Menon, M ;

Milam, DF ;

Ramsdell, JW ;

Schenkman, NS ;

Slawin, KM ;

Smith, JA ;

Kusek, JW ;

Nyberg, LM ;

Briggs, JP ;

McConnell, JD ;

Crawford, ED ;

Homan, K ;

Donohue, R ;

Parker, D ;

Easterday, K ;

Robertson, K ;

Kaplan, S ;

Wentland, M ;

Hardy, L ;

Roehrborn, C ;

Ahrens, A ;

McConnell, J ;

Hall, D ;

Cutts, D ;

Carter, S ;

Waldrep, K ;

Schenkman, N ;

Sanetrik, K ;

Sihelnik, S ;

Zorn, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2387-2398

[6] Should routine screening for prostate-specific antigen be recommended? [J].

Oottamasathien, S ;

Crawford, ED .

ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (06) :661-662

[7] Prostate-specific antigen change in the European Randomized Study of screening for prostate cancer, section Rotterdam [J].

Raaijmakers, R ;

Wildhagen, MF ;

Ito, K ;

Pàez, A ;

De Vries, SH ;

Roobol, MJ ;

Schröder, FH .

UROLOGY, 2004, 63 (02) :316-320

[8] The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? [J].

Stamey, TA ;

Caldwell, M ;

McNeal, JE ;

Nolley, R ;

Hemenez, M ;

Downs, J .

JOURNAL OF UROLOGY, 2004, 172 (04) :1297-1301

[9] Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter [J].

Thompson, IM ;

Pauler, DK ;

Goodman, PJ ;

Tangen, CM ;

Lucia, MS ;

Parnes, HL ;

Minasian, LM ;

Ford, LG ;

Lippman, SM ;

Crawford, ED ;

Crowley, JJ ;

Coltman, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (22) :2239-2246

[10] The influence of finasteride on the development of prostate cancer [J].

Thompson, IM ;

Goodman, PJ ;

Tangen, CM ;

Lucia, MS ;

Miller, GJ ;

Ford, LG ;

Lieber, MM ;

Cespedes, RD ;

Atkins, JN ;

Lippman, SM ;

Carlin, SM ;

Ryan, A ;

Szczepanek, CM ;

Crowley, JJ ;

Coltman, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (03) :215-224

← 1 2 →